These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31954695)

  • 1. CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo.
    Ni J; Cheung BB; Beretov J; Duan W; Bucci J; Malouf D; Graham P; Li Y
    Exp Cell Res; 2020 Mar; 388(2):111850. PubMed ID: 31954695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo.
    Ni J; Cozzi P; Beretov J; Duan W; Bucci J; Graham P; Li Y
    BMC Cancer; 2018 Nov; 18(1):1092. PubMed ID: 30419852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
    Ni J; Cozzi PJ; Hao JL; Beretov J; Chang L; Duan W; Shigdar S; Delprado WJ; Graham PH; Bucci J; Kearsley JH; Li Y
    Prostate; 2014 May; 74(6):602-17. PubMed ID: 24615685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
    Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
    PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
    Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway.
    Jijiwa M; Demir H; Gupta S; Leung C; Joshi K; Orozco N; Huang T; Yildiz VO; Shibahara I; de Jesus JA; Yong WH; Mischel PS; Fernandez S; Kornblum HI; Nakano I
    PLoS One; 2011; 6(9):e24217. PubMed ID: 21915300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways.
    Lu X; Yang F; Chen D; Zhao Q; Chen D; Ping H; Xing N
    Int J Biol Sci; 2020; 16(7):1121-1134. PubMed ID: 32174789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance.
    Jung T; Gross W; Zöller M
    J Biol Chem; 2011 May; 286(18):15862-74. PubMed ID: 21372142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.
    Li X; Song Y; Zhang P; Zhu H; Chen L; Xiao Y; Xing Y
    Tumour Biol; 2016 Jun; 37(6):7599-613. PubMed ID: 26687646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
    Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer.
    Leake K; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
    PLoS One; 2012; 7(4):e34582. PubMed ID: 22509328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
    Hou Y; Li H; Huo W
    Prostate; 2020 Jul; 80(10):753-763. PubMed ID: 32421868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOTAIR/miR-326/FUT6 axis facilitates colorectal cancer progression through regulating fucosylation of CD44 via PI3K/AKT/mTOR pathway.
    Pan S; Liu Y; Liu Q; Xiao Y; Liu B; Ren X; Qi X; Zhou H; Zeng C; Jia L
    Biochim Biophys Acta Mol Cell Res; 2019 May; 1866(5):750-760. PubMed ID: 30742932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 is a biomarker associated with human prostate cancer radiation sensitivity.
    Xiao W; Graham PH; Power CA; Hao J; Kearsley JH; Li Y
    Clin Exp Metastasis; 2012 Jan; 29(1):1-9. PubMed ID: 21953074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer.
    Su B; Gao L; Baranowski C; Gillard B; Wang J; Ransom R; Ko HK; Gelman IH
    PLoS One; 2014; 9(7):e101411. PubMed ID: 24983969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.
    Hao J; Graham P; Chang L; Ni J; Wasinger V; Beretov J; Deng J; Duan W; Bucci J; Malouf D; Gillatt D; Li Y
    Oncotarget; 2016 Nov; 7(45):74269-74285. PubMed ID: 27708237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
    Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
    Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.